Hypertriglyceridemia and ischemic stroke

European Neurology

Volumn 60, Issue 6, 2008, Pages 269-278

  Antonios, Nader ^a   Angiolillo, Dominick J ^a   Silliman, Scott ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Hypertriglyceridemia; Ischemic stroke; Triglycerides, stroke risk

Indexed keywords

ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOFIBRATE; CORTICOSTEROID; ESTROGEN; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PLACEBO; PRAVASTATIN; RETINOID; SIMVASTATIN; TRIACYLGLYCEROL;

BRAIN ATHEROSCLEROSIS; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG MECHANISM; DRUG MEGADOSE; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

HUMANS; HYPERTRIGLYCERIDEMIA; RISK FACTORS; STROKE; TRIGLYCERIDES;

EID: 52549087817     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000157880     Document Type: Review

References (52)

1. Koren-Morag N, Tanne D, Graff E, Goldbourt U, the Benzafibrate Infarction Prevention Study Group: Low- and high-density lipoprotein cholesterol and ischemic cerebrovascular disease: the bezafibrate infarction prevention registry. Arch Intern Med 2002;162:993-999.
2. Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, Gorelick P, Halperin J, Harbaugh R, Johnston SC, Katzan I, Kelly-Hayes M, Kenton EJ, Marks M, Schwamm LH, Tomsick T: Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke, cosponsored by the Council on Cardiovascular Radiology and Intervention. Stroke 2006;37:577-617.
3. http://www.accessmedicine.com (accessed December 1, 2006).
4. http://en.wikipedia.org/wiki/Triglyceride (accessd June 4, 2006).
5. Wittrup HH, Anderson RV, Tybjaerg-Hansen A, Jensen GB, Nordestgaard BG: Combined analysis of six lipoprotein lipase genetic variants on triglycerides, high-density lipoprotein, and ischemic heart disease: cross-sectional, prospective, and case-control studies from the Copenhagen City Heart Study. J Clin Endocrinol Metab 2006;91:1438-1445.
6. Wittrup HH, Tybjaerg-Hansen A, Jensen GB, Nordestgaard BG: Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. Circulation 1999;99:2901-2907.
7. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143.
8. www.emedicine.com (accessed February 22, 2007).
9. Austin MA, Hokanson JE, Edwards KL: Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998;81:7B-12B.
10. Anderson RA, Evans ML, Ellis GR, Graham J, Morris K, Jackson SK, Lewis MJ, Rees A, Frenneaux MP: The relationships between post-prandial lipaemia, endothelial function and oxidative stress in health individuals and patients with type 2 diabetes. Atherosclerosis 2001;154:475-483.
11. Mack WJ, Krauss RM, Hodis HN: Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression. Arterioscler Thromb Vasc Biol 1996;16:697-704.
12. Lundman P, Eriksson M, Schenck-Gustafsson K, Karpe F, Tornvall P: Transient triglyceridemia decreases vascular reactivity in young, healthy men without risk factors for coronary heart disease. Circulation 1997;96:3266-3268.
13. Lewis TV, Dart AM, Chin-Dusting JP: Endothelium-dependent relaxation by acetylcholine is impaired in hypertriglyceridemic humans with normal levels of plasma LDL cholesterol. J Am Coll Cardiol 1999;33:805-812.
14. Abe Y, El-Masri B, Kimball KT, Pownall H, Reilly CF, Osmundsen K, Smith CW, Ballantyne CM: Soluble cell adhesion molecules in hypertriglyceridemia and potential significance on monocyte adhesion. Arterioscler Thromb Vasc Biol 1998;18:723-731.
15. Hackman A, Abe Y, Insull W Jr, Pownall H, Smith L, Dunn K, Gotto AM Jr, Ballantyne CM: Levels of soluble cell adhesion molecules in patients with dyslipidemia. Circulation 1996;93:1334-1338.
16. Papagianni A, Kokolina E, Kalovoulos M, Vainas A, Dimitriadis C, Memmos D: Carotid atherosclerosis is associated with inflammation, malnutrition and intercellular adhesion molecule-1 in patients on continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 2004;19:1258-1263.
17. Cannon CP: Lipids Online. http://www.lipidsonline.org/slides01-10.cfm?q= bmi&dpg=6 (accessed March 16, 2006).
18. Heilbronn UK, Noakes M, Clifton PM: Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women. Arterioscler Thromb Vasc Biol 2001;21:968-970.
19. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-1565.
20. Fine-Edelstein JS, Wolf PA, O'Leary DH, Poehlman H, Belanger AJ, Kase CS, D'Agostino RB: Precursors of extracranial carotid atherosclerosis in the Framingham study. Neurology 1994;44:1046-1050.
21. Teno S, Uto Y, Nagashima H, Endoh Y, Iwamoto Y, Omori Y, Takizawa T: Association of postprandial hypertriglyceridemia and carotid intima-media thickness in patients with type 2 diabetes. Diabetes Care 2000;23:1401-1406.
22. Ryu JE, Howard G, Craven TE, Bond MG, Hagaman AP, Crouse JR 3rd: Postprandial triglyceridemia and carotid atherosclerosis in middle-aged subjects. Stroke 1992;23:823-828.
23. Simpson HC, Mann JI, Meade TW, Chakrabarti R, Stirling Y, Woolf L: Hypertriglyceridaemia and hypercoagulability. Lancet 1983;i:786-790.
24. Mauriello A, Sangiorgi G, Palmieri G, Virmani R, Holmes DR Jr, Schwartz RS, Pistolese R, Ippoliti A, Spagnoli LG: Hyperfibrinogenemia is associated with specific histocytological composition and complications of atherosclerotic carotid plaques in patients affected by TIA. Circulation 2000;101:744-750.
25. Szirmai IG, Kamondi A, Magyar H, Juhasz C: Relation of laboratory and clinical variables to the grade of carotid atherosclerosis. Stroke 1993;24:1811-1816.
26. Rosenson RS, Shott S, Lu L, Tangney CC: Hypertriglyceridemia and other factors associated with plasma viscosity. Am J Med 2001;110:488-492.
27. Rosenson RS: Approach to the patient with hypertriglyceridemia. UpToDate. http://www.utdol.com/application/topic/topic-Text.asp?file=lipiddis/ 9849&type=A&selectedTitle=1~55 (accessed October 10, 2005).
28. Seplowitz AH, Chien S, Smith FR: Effects of lipoproteins on plasma viscosity. Atherosclerosis 1981;38:89-95.
29. Leonhardt H, Arntz HR, Klemens UH: Studies of plasma viscosity in primary hyperlipoproteinemia. Atherosclerosis 1977;28:29-40.
30. Stein JH, Rosenson RS: Treatment of severe hypertriglyceridemia lowers plasma viscosity. Atherosclerosis 1998;137:401-405.
31. Coughlan BJ, Sorrentino MJ: Does hypertriglyceridemia increase risk for CAD? Postgrad Med 2000;108:77-84.
32. Kreisberg RA: Diabetic dyslipidemia. Am J Cardiol 1998;82:67U-73U.
33. StancákováA, BaldaufováL, Javorský M, KozárováM, Salagovic J, Tkác I:: Effect of gene polymorphisms on lipoprotein levels in patients with dyslipidemia of metabolic syndrome. Physiol Res 2006;55:483-490.
34. Schneider DJ: Abnormalities of coagulation, platelet function, and fibrinolysis associated with syndromes of insulin resistance. Coron Artery Dis 2005;16:473-476.
35. Zevitz ME: Hypertriglyceridemia and cardiovascular disease. eMedicine. http://www.emedicine.com (accessed January 2, 2006).
36. Ninomiya JK, L'Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS: Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 2004;109:42-46.
37. Bowman TS, Sesso HD, Ma J, Kurth T, Kase CS, Stampfer MJ, Gaziano JM: Cholesterol and the risk of ischemic stroke. Stroke 2003;34:2930-2934.
38. Simons LA, McCallum J, Friedlander Y, Simons J: Risk factors for ischemic stroke: Dubbo Study of the elderly. Stroke 1998;29:1341-1346.
39. Sridharan R: Risk factors for ischemic stroke: a case control analysis. Neuroepidemiology 1992;11:24-30.
40. Rossner S, Kjellin KG, Mettinger KL, Siden A, Soderstrom CE: Normal serum-cholesterol but low HDL-cholesterol concentration in young patients with ischemic cerebrovascular disease. Lancet 1978;i:577-579.
41. Aronow WS, Gutstein H, Lee NH, Edwards M: Three-year follow-up of risk factors correlated with new atherothrombotic brain infarction in 708 elderly patients. Angiology 1988;39:563-566.
42. Shahar E, Chambless LE, Rosamond WD, Bolland LL, Ballantyne CM, McGovern PG, Sharrett AR: Plasma lipid profile and incident ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study. Stroke 2003;34:623-631.
43. Tanne D, Koren-Morag N, Graff E, Goldbourt U, the BIP Study Group: Blood lipids and first-ever ischemic stroke/transient ischemic attack in the Bezafibrate Infarction Prevention (BIP) Registry: high triglycerides constitute an independent risk factor. Circulation 2001;104:2892-2897.
44. Patel A, Barzi F, Jamrozik K, Lam TH, Ueshima H, Whitlock G, Woodward M, Asia Pacific Cohort Studies Collaboration: Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation 2004;110:2678-2686.
45. Njølstad I, Arnesen E, Lund-Larsen PG: Body height, cardiovascular risk factors and risk of stroke in middle-aged men and women. A 14-year follow-up of the Finnmark Study. Circulation 1996;94:2877-2882.
46. Lindenstrom E, Boysen G, Nyboe J: Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenhagen City Heart Study. BMJ 1994;309:11-15.
47. Laloux P, Galanti L, Jamat J: Lipids in ischemic stroke subtypes. Acta Neurol Belg 2004;104:13-19.
48. Slowik A, Iskra T, Turaj W, Hartwich J, Dembinska-Kiec A, Szczudlik A: LDL phenotype B and other lipid abnormalities in patients with large vessel disease and small vessel disease. J Neurol Sci 2003;214:11-16.
49. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, Maenpaa H, Malkonen M, Manttari M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjoblom T, Nikkila EA: Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-1245.
50. Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN, Basayannis EO, Demitriadis DS, Kontopoulos AG: Treatment with atorvastatin to the National Cholesterol Education Program goal versus 'usual' care in secondary coronary heart disease prevention: the Greek Atorvastatin and Coronary-Heart-Disease Evaluation (GREACE) study. Curr Med Res Opin 2002;18:220-228.
51. Rubins HB, Robins SJ, Collins D, Anderson JW, Elam MB, Faas FH, Linares E, Sachaefer EJ, Schectman G, Wilt TJ, Wittes J: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410-418.
52. Rubins HB, Davenport J, Babikian V, Brass LM, Collins D, Wexler L, Wagner S, Papademetriou V, Rutan G, Robins S, the VA-HIT Study Group: Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol. The Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation 2001;103:2828-2833.